Askel’s deep tech solution, COPLA®, focuses on early intervention and prevention of joint surface degradation. COPLA®, is a medical device already in use for the benefit of veterinary patients. The next step is to move forward to treat human patients. To reach this milestone, the company has announced a share issue on the crowdfunding platform Invesdor (www.invesdor.com/askel). The crowdfunding is open until the end of January 2020.
COPLA® is used as a platform in RESTORE project to create 2nd generation COPLA® by building nanoenabled 3D matrix for efficient cartilage repair. By joining Askel’s crowdfunding campaign you can also be part of Askel’s story.